Pipeline

MBF-118

MBF-118 represents the first potent and selective PPAR-γ antagonist to be explored as a novel immunotherapy in solid tumors.

MBF-015

MBF-015 represents a novel and selective histone deacetylase 1/2 inhibitor for the treatment of cancer.

MBF-226

MBF-226 Selective prostaglandin receptors (EP4) antagonistsfor the treatment of solid tumors

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the mentioned cookies and the acceptance of our Cookies policy.
. ACEPTAR

Aviso de cookies